Contact information
+44 (0) 1865 572898
Colleges
Ileana Badi
PhD
Senior Postdoctoral Researcher
My principal research interests lie in understanding the cellular and molecular mechanisms leading to cardiovascular disease. I obtained my Ph.D. in 2008 at the University of Insubria (Italy), where I studied the role of the transcription factor Ankrd1 in the pathogenesis of the rare congenital heart disease Total Anomalous Pulmonary Venous Return (TAPVR). Hence, I decided to deepen my knowledge on the transcriptional control of cardiac development in Professor Vincent M. Christoffels’s lab at the University of Amsterdam. There, I studied the transcriptional regulation of Tbx3 gene that encodes a transcription factor important for the conduction system and arterial pole morphogenesis. At this point I felt the need to move towards more translational studies; thus, I spent six years at the Centro Cardiologico Monzino, in Milan, where I focused my attention on the role of miR-34a in vascular “inflammaging” and vascular calcification, as this microRNA could be a promising therapeutic target for cardiovascular disease. In June 2018 I joined The Oxford Translational Cardiovascular Research Group, that superbly combines basic science and clinical research. Here, I am keen on studying how the cross-talk between adipose tissue and the cardiovascular system can affect cardiovascular disease.
Recent publications
-
Myocardial overexpression of ANKRD1 causes sinus venosus defects and progressive diastolic dysfunction.
Journal article
Piroddi N. et al, (2020), Cardiovasc Res, 116, 1458 - 1472
-
The microRNA-34a-Induced Senescence-Associated Secretory Phenotype (SASP) Favors Vascular Smooth Muscle Cells Calcification.
Journal article
Zuccolo E. et al, (2020), Int J Mol Sci, 21
-
Insulin-induced vascular redox dysregulation in human atherosclerosis is ameliorated by dipeptidyl peptidase 4 inhibition.
Journal article
Akoumianakis I. et al, (2020), Sci Transl Med, 12
-
Myocardial redox state predicts 3-year mortality in patients undergoing cardiac surgery: the ox-HVF study
Conference paper
Kotanidis C. et al, (2019), EUROPEAN HEART JOURNAL, 40, 3886 - 3886
-
Novel direct effects of SGLT2 inhibitor, Canagliflozin, on myocardial redox state in humans
Conference paper
Kondo H. et al, (2019), EUROPEAN HEART JOURNAL, 40, 3872 - 3872